Headquartered in Herzliya, the Israeli pharmaceutical received the go-ahead from the FDA to commence advanced trials in the U.S. on its long-lasting pain-killer, confidant it will replace the commonly used and highly addictive opiate-based medicines.
By REUTERS
JERUSALEM – Israeli pharmaceuticals company PainReform has received approval from the US Food and Drug Administration (FDA) to begin late-stage clinical studies for a pain relief drug that is a departure from opiate-based narcotics, it said on Tuesday.
Many patients today dealing with pain after surgery are prescribed opioids, which can be highly addictive and are at the heart of a costly health crisis in the United States. Continue Reading »